Nimesulide in Beta-Cyclodextrin

A formulation of Nimesulide in Beta-Cyclodextrin, is the out come of Novel Drug Delivery System. Beta-Cyclodextrin, produced by enzymatic hydrolysis of common starch has a particular chemical structure that enables it to form inclusion complex with various drugs. In this way it is able to improve solubility, stability and bioavailability. Nimesulide in Beta-Cyclodextrin is very soluble in water and has more rapid and complete absorption than plain Nimesulide after oral administration. The improved solubility leads to a rapid increase in analgesic and anti-inflammatory effect.

Indications

Painful inflammatory conditions associated with - Musculoskeletal system, Dysmenorrhea, Thrombophlebitis, Dental pain, ENT infection, Osteoarthritis, Low back pain, Post operative pain, Fever, Rheumatoid arthritis, Gynecological disorder

Dosage

Adult: Per tablet contains nimesulide 100 mg and racemethionine 50 mg: 1 tablet bid. Child: 5 mg/kg/day (Nimesulide) divided in 2-3 daily doses.

Contra-Indications

Active peptic ulcer, moderate-to-severe hepatic impairment. Pregnancy, lactation.

Special Precautions

1.Renal impairment 2.Heart failure 3.Cirrhosis 4.Vol or salt depleted patients 5.Metabolic acidosis, 6.Patients with a history of severe hepatic impairment

Side Effects

Nausea, Vomiting, Diarrhoea, Increased liver enzymes

Drug Interactions

Fenofibrate, salicylic acid, valproic acid and tolbutamide displace nimesulide from its plasma binding sites. Nimesulide displaces methotrexate and furosemide from plasma proteins. Nimesulide should be used with caution along with warfarin since efficacy may be increased. Nimesulide may decrease the efficacy of slow release theophylline preparations. Concurrent use of levodopa with racemethionine may decrease the therapeutic effects of levodopa.